ExPretio has been sold to Modaxo
The shareholders of ExPretio have sold the company to Modaxo.
Founded in 2005, ExPretio is the leading provider of revenue management optimization solutions and software to the rail and bus passenger industry. ExPretio’s flagship product, Appia, serves the world’s largest rail operators, generating price and inventory recommendations for more than 300 million passengers per year.
Modaxo is a division of Constellation Software Inc, a Canadian global technology leader, with a market cap of US$40 billion. Modaxo’s portfolio of more than 20 companies is entirely dedicated to enhancing people’s mobility through technology.
Oaklins’ teams in France and Canada served as exclusive sell-side advisor, managing the sale process of ExPretio from beginning to successful completion. This strategic transaction provides a strong demonstration, not only of Oaklins’ expertise in the enterprise software industry, but also of Oaklins’ unique ability to deliver successful M&A and carveout projects in a challenging cross-border context.
Talk to the deal team
Related deals
Niscon Inc. has been acquired by SGPS ShowRig
Niscon Inc. has been successfully acquired by SGPS ShowRig, a global provider of staging, rigging and automation for live entertainment. The acquisition reinforces SGPS Showrig’s commitment to pushing the boundaries of innovation in the entertainment industry. By adding Niscon’s unique motion-control technology to its portfolio, SGPS Showrig strengthens its ability to deliver cutting-edge, precision-driven solutions.
Learn moreFairfest Media has acquired WTE Miami
Fairfest Media, organizer of OTM, the leading travel show in Asia, has acquired WTE Miami, the fastest-growing travel trade show in the USA. The acquisition marks a significant milestone in Fairfest’s global expansion, strengthening its presence in the Americas and beyond by leveraging decades of experience and leadership in Asia and India.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more